| 초록 |
Objectives: This study aimed to evaluate hemoglobin variability in patients with chronic kidney disease (CKD) according to decline in kidney function.
Methods: We analyzed patients from the KoreaN cohort study for Outcome in patients With CKD (KNOW-CKD). Rapid decline in kidney function was defined as a decline in the estimated glomerular filtration rate (eGFR) of >3 mL/min/1.73 m2/year. Hemoglobin value was measured at 0, 6, and 12 month and annually for up to 8 years. Hemoglobin variability was calculated by standard deviation. Higher hemoglobin variability was defined as a hemoglobin variability value greater than the median.
Results: Among 1895 patients, 736 (38.8 %) were in the rapid kidney function decline group. In 1472 patients who were 1:1 propensity score-matched, the baseline eGFR was not significantly different between the non-rapid and rapid kidney function decline groups (48.2 ± 26.9 vs 46.9 ± 26.2 ml/min/1.73m2, P = 0.345). The use of iron supplements (P = 0.536) or erythropoiesis stimulating agents (P = 0.699) was similar in both groups. In multivariable logistic regression analysis, rapid decline in kidney function was significantly associated with higher hemoglobin variability (odds ratio [OR]: 1.81; 95% confidence interval [CI]: 1.432.28; P < 0.001). This association was prominent in the group without anemia at baseline (OR: 2.82; 95% CI: 1.994.01; P < 0.001).
Conclusions: Rapid decline in kidney function is associated with higher hemoglobin variability in patients with CKD. Attention should be paid to hemoglobin variability in patients with a rapid decline in kidney function.
|